Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world

被引：4
|
作者：
Ogura, Takashi [1 ]
Kitamura, Hideya [1 ]
机构：
[1] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
来源：
RESPIROLOGY | 2017年 / 22卷 / 06期
关键词：
idiopathic pulmonary fibrosis; nintedanib; pirfenidone; therapeutics; tolerability; RANDOMIZED-TRIALS; SAFETY;
D O I：
10.1111/resp.13059
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：1051 / 1052
页数：2
相关论文
共 50 条
  • [1] Real World Experience of Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
    Mulholland, S. A.
    Al Jbour, K.
    Steer, H.
    Gutsche, M.
    Foley, N.
    Srivastava, R.
    Sharp, C.
    Adamali, H. I.
    Barratt, S.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [2] Pirfenidone And Nintedanib For Pulmonary Fibrosis In Real-World Clinical Practice: Tolerability And Adverse Drug Reactions
    Galli, J. A.
    Pandya, A.
    Vega-Olivio, M.
    Criner, G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [3] Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis
    Sathiyamoorthy, Gayathri
    Sehgal, Sameep
    Ashton, Rendell W.
    [J]. SOUTHERN MEDICAL JOURNAL, 2017, 110 (06) : 393 - 398
  • [4] Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients
    Fournier, D.
    Jouneau, S.
    Bouzille, G.
    Polard, E.
    Osmont, M. N.
    Scailteux, L. M.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 77 - 78
  • [5] Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients
    Fournier, Dorine
    Jouneau, Stephane
    Bouzille, Guillaume
    Polard, Elisabeth
    Osmont, Marie-Noëlle
    Scailteux, Lucie-Marie
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2022, 76
  • [6] A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world
    Nakamura, Masayuki
    Okamoto, Masaki
    Fujimoto, Kiminori
    Ebata, Tomohiro
    Tominaga, Masaki
    Nouno, Takashi
    Zaizen, Yoshiaki
    Kaieda, Shinjiro
    Tsuda, Tohru
    Kawayama, Tomotaka
    Hoshino, Tomoaki
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (12)
  • [7] Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions
    Galli, Jonathan A.
    Pandya, Aloknath
    Vega-Olivo, Michelle
    Dass, Chandra
    Zhao, Huaqing
    Criner, Gerard J.
    [J]. RESPIROLOGY, 2017, 22 (06) : 1171 - 1178
  • [8] Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
    Hughes, Gareth
    Toellner, Hannah
    Morris, Helen
    Leonard, Colm
    Chaudhuri, Nazia
    [J]. JOURNAL OF CLINICAL MEDICINE, 2016, 5 (09)
  • [9] Pirfenidone vs nintedanib for treatment of idiopathic pulmonary fibrosis in clinical practice: efficacy, tolerability, and adverse effects
    Sadon, Amal A. E-A
    Kenawy, Ahmed S.
    Abdelsalam, Ashraf H.
    Attia, Hosam M.
    [J]. EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2020, 69 (03): : 549 - 559
  • [10] Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis
    Sugino, Keishi
    Ono, Hirotaka
    Saito, Mikako
    Ando, Masahiro
    Tsuboi, Eiyasu
    [J]. PLOS ONE, 2024, 19 (06):
12345